|
Age (years), median (range)
|
63 (23–81)
|
58 (22–86)
|
0.10
|
|
Gender, male
|
26 (59)
|
46 (60)
|
0.94
|
|
Diagnosis of IA
| | |
0.06
|
|
Definite IA
|
4/43 (9)
|
18 (23)
| |
|
Probable IA
|
39/43 (91)
|
59 (77)
| |
|
Invasive pulmonary infection a
|
40 (91)
|
68 (88)
|
0.77
|
|
Disseminated infectiona
|
2 (5)
|
6 (8)
|
0.71
|
|
Localized or sinus infectiona
|
4 (9)
|
3 (4)
|
0.25
|
|
Leukemia
|
19 (43)
|
55 (71)
|
0.002
|
|
Lymphoma
|
16 (36)
|
16 (21)
|
0.06
|
|
Myeloma
|
8 (18)
|
4 (5)
|
0.029
|
|
Transplantation within 1 year prior to infection
|
16 (36)
|
34 (44)
|
0.40
|
|
Type of transplantation within prior year
| | |
0.14
|
|
Allogeneic transplant
|
10/16 (63)
|
29/34 (85)
| |
|
Autologous transplant
|
6/16 (38)
|
5/34 (15)
| |
|
Graft vs Host Disease (GVHD)
|
8/10 (80)
|
22/29 (76)
|
> .99
|
|
Neutropenia (< 500 ANC) at onset of IA
|
8/42 (19)
|
29/73 (40)
|
0.022
|
|
Persistent neutropenia
|
14/36 (39)
|
21/64 (33)
|
0.54
|
|
Received immunotherapy
|
10/43 (23)
|
37/76 (49)
|
0.006
|
|
Received WBC transfusion
|
2/42 (5)
|
8 (10)
|
0.49
|
|
Year of IA diagnosis/treatment
| | |
0.73
|
|
1993–2004
|
8 (18)
|
16 (21)
| |
|
2005–2016
|
36 (82)
|
61 (79)
| |
|
Prophylactic antifungal treatment prior to
|
7 (16)
|
27/76 (36)
|
0.022
|
|
infection
| | | |
|
Breakthrough
|
6/7 (86)
|
25/26 (96)
|
0.38
|
|
Response to therapy
|
32 (73)
|
39 (51)
|
0.018
|
|
Death within 42 days of starting therapy
|
2 (5)
|
7/76 (9)
|
0.48
|
|
Aspergillosis-attributable death within 42 days of starting therapy
|
2 (5)
|
6/76 (8)
|
0.71
|
